Human anti-equine immunoglobulin antibodies (HAEA)

Human anti-equine immunoglobulin antibodies (HAEA) are anti-drug antibodies (ADAs) produced by the human immune system in response to the administration of horse-derived proteins, such as equine antithymocyte globulin (Atgam) or various antitoxins [FDA, Atgam Label]. These antibodies recognize foreign epitopes on the equine immunoglobulin structure, leading to the formation of circulating immune complexes [Bielory et al., 1988, J. Clin. Invest.]. The primary clinical manifestation of this interaction is serum sickness, a Type III hypersensitivity reaction characterized by fever, arthralgia, and urticaria [StatPearls, Serum Sickness]. Mechanistically, the HAEA-antigen complexes deposit in small blood vessels and tissues, triggering the classical complement pathway and recruiting immune effector components such as C1q, C3, and C4, as well as activating Fc-receptor-bearing cells like neutrophils [Janeway's Immunobiology]. This process not only causes systemic inflammation and potential organ damage, such as glomerulonephritis, but also significantly reduces the half-life and efficacy of the equine-derived therapeutic [Lawnsby et al., 2023, Toxins]. Consequently, HAEAs are a major limiting factor in the clinical use of xenogeneic antibodies, necessitating careful monitoring of patient titers and complement levels [Mayo Clinic].

Other names

Human anti-horse antibodiesAnti-equine IgGEquine-induced anti-drug antibodiesSerum sickness antibodiesHuman anti-equine immunoglobulin antibodies and immune effector components

Human anti-equine antibodies (HAEA) are not therapeutic targets; rather, they are anti-drug antibodies that bind to equine-derived proteins to form immune complexes, which then activate the complement system and facilitate the clearance of the therapeutic agent [StatPearls, Serum Sickness].